{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:43:20Z","timestamp":1776822200459,"version":"3.51.2"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Primary membranoproliferative glomerulonephritis (MPGN) is an ultrarare disease characterized by immunofluorescence microscopy as either immune-complex mediated (IC-MPGN) or C3 glomerulopathy (C3), the latter subdivided by electron microscopy to C3 glomerulonephritis (C3GN) and dense deposit disease (DDD). Both IC-MPGN and C3G typically have obvious C3 staining differentiating them from other causes of MPGN histology. Secondary causes must be excluded, including infections, autoimmune disease, and neoplasia. Clinical presentations are variable, including urinary sediment abnormalities, nephrotic syndrome, or a rapidly progressive course. The prognosis is unfavorable with about 50% reaching kidney failure by 10 years. Recurrence following transplantation is frequent, and allograft survival is shortened. The pathogenesis involves dysregulation of the alternate pathway (AP) of complement. Possibly 20% of patients harbor pathogenic mutations in AP proteins or their regulators, and up to 80% have autoantibodies impairing normal regulation. Paraproteins are found in 20 \u2013 40% of otherwise primary MPGN, either directly detectable on biopsy (IC-MPGN) or as dysregulators of the AP. Therapy of MPGN begins with supportive care as for all glomerulopathies. Paraproteins require clone-directed therapy. When immunosuppression is considered, complement inhibition should be first line. Two agents are now FDA approved for C3G, the oral Factor B inhibitor iptacopan and the subcutaneous C3-inhibitor pegcetacoplan, the latter also approved for IC-MPGN. If complement inhibition is unavailable, MMF\/steroids may be considered. Following transplantation, protocol biopsies are needed to detect early recurrence with the intent of complement inhibition.<\/jats:p>","DOI":"10.3389\/fneph.2026.1747678","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:27Z","timestamp":1770960147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment"],"prefix":"10.3389","volume":"6","author":[{"given":"Edward J.","family":"Filippone","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University","place":["Philadelphia, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Farber","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sidney Kimmel Medical College at Thomas Jefferson University","place":["Philadelphia, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.02.013","article-title":"Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy","volume":"105","author":"Madden","year":"2024","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100874","article-title":"Apolipoprotein E immunostaining has diagnostic utility in differentiating dense deposit disease and C3 glomerulonephritis: clone-based evaluation of D719N, EP1373Y, and 1B2C9","volume":"38","author":"Hurdogan","year":"2025","journal-title":"Modern Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10157-017-1513-7","article-title":"Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015","volume":"22","author":"Nakagawa","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1590\/2175-8239-JBN-2022-0016en","article-title":"Membranoproliferative glomerulonephritis: current histopathological classification, clinical profile, and kidney outcomes","volume":"45","author":"Bernardes","year":"2023","journal-title":"J Bras Nefrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.26442\/00403660.2018.12.000007","article-title":"Membranoproliferative glomerulonephritis in Russian population","volume":"90","author":"Dobronravov","year":"2018","journal-title":"Ter Arkh"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04078-3","article-title":"Clinical characteristics and short term outcomes of childhood immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy: a single centre retrospective study","volume":"26","author":"Bajeer","year":"2025","journal-title":"BMC Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000185969","article-title":"Long-term prognosis of membranoproliferative glomerulonephritis type I: significance of clinical and morphological parameters: an investigation of 220 cases","volume":"55","author":"Schmitt","year":"2008","journal-title":"Nephron"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.029","article-title":"1196 C3G and ic-MPGN across the life span: findings from the European Rare Kidney Disease Registry","volume":"39","author":"Schaefer","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.06.003","article-title":"Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry","volume":"108","author":"Masoud","year":"2025","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.019","article-title":"Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children","volume":"5","author":"Kirpalani","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.24.129","article-title":"Clinical features and outcomes of immune complex-membranoproliferative glomerulonephritis and C3 glomerulopathy: a multicenter observational cohort study analyzing kidney biopsy cases","author":"Kim","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11830720","article-title":"Inherited kidney complement diseases","volume":"16","author":"Lemaire","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195821","article-title":"Structures of C3b in complex with factors B and D give insight into complement convertase formation","volume":"330","author":"Forneris","year":"2010","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.670727","article-title":"CFH and CFHR copy number variations in C3 glomerulopathy and immune complex-mediated membranoproliferative glomerulonephritis","volume":"12","author":"Piras","year":"2021","journal-title":"Front Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation","volume":"123","author":"Tortajada","year":"2013","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz021","article-title":"Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy","volume":"34","author":"Frangou","year":"2019","journal-title":"Nephrol Dialysis Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40246-015-0029-z","article-title":"Complement regulator CD46: genetic variants and disease associations","volume":"9","author":"Liszewski","year":"2015","journal-title":"Hum Genomics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015040385","article-title":"High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000252","article-title":"Rare variants in complement gene in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative GN","volume":"18","author":"Meuleman","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019040433","article-title":"Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019338108","article-title":"Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk","volume":"108","author":"Heurich","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1038\/s41598-017-05173-8","article-title":"A haplotype in CFH family genes confers high risk of rare glomerular nephropathies","volume":"7","author":"Ding","year":"2017","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05221-6","article-title":"Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort","volume":"37","author":"Michels","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1237-8","article-title":"C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy","volume":"14","author":"Garam","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1640-3","article-title":"Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis","volume":"20","author":"Li","year":"2019","journal-title":"BMC Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.7.1723","article-title":"Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome","volume":"14","author":"Andresdottir","year":"1999","journal-title":"Nephrology dialysis Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-015-0219-x","article-title":"Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification","volume":"17","author":"Alasfar","year":"2016","journal-title":"BMC Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac148","article-title":"Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation","volume":"38","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Nephrol Dialysis Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000474","article-title":"C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation","volume":"19","author":"Tarrag\u00f3n","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ekir.2024.10.008","article-title":"Outcome of patients transplanted for C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis","volume":"10","author":"Halfon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.10.019","article-title":"Evaluation for genetic disease in kidney transplant candidates: A practice resource","volume":"25","author":"Ames","year":"2025","journal-title":"Am J Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf134","article-title":"Kidney transplant in patients with C3 glomerulopathy","volume":"18","author":"Attieh","year":"2025","journal-title":"Clin Kidney J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000751","article-title":"Clinical and histologic predictors of kidney outcomes in C3 glomerulopathy and idiopathic membranoproliferative GN","volume":"20","author":"Ghaddar","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 Experience at mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clinic Proc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex\u2013mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.08.035","article-title":"Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy","author":"Benigni","year":"2025","journal-title":"Kidney Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06760909","article-title":"Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy","volume":"5","author":"Sethi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy\u2013associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh526","article-title":"Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids","volume":"19","author":"Jones","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.5414\/cnp73354","article-title":"Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis","volume":"73","author":"Yuan","year":"2010","journal-title":"Clin Nephrol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy127","article-title":"Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy","volume":"12","author":"Bharati","year":"2018","journal-title":"Clin Kidney J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2478\/prilozi-2019-0010","article-title":"Evaluation of clinical, laboratory and treatment modalities in C3 glomerulopathy: single center experience","volume":"40","author":"Yeter","year":"2019","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04799-7","article-title":"Predictors of poor kidney outcome in children with C3 glomerulopathy","volume":"36","author":"P\u0131narba\u015f\u0131","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2180508","article-title":"Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"2017","author":"Rudnicki","year":"2017","journal-title":"BioMed Res Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.02.1402","article-title":"Clinical remission and reduction of circulating nephritic factors by combining rituximab with belimumab in a case of complement factor 3 glomerulopathy","volume":"9","author":"van Schaik","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000505","article-title":"Developing therapies for C3 glomerulopathy: report of the kidney health initiative C3 glomerulopathy trial endpoints work group","volume":"19","author":"Nester","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease","volume":"366","author":"Daina","year":"2012","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis","volume":"366","author":"Radhakrishnan","year":"2012","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad182","article-title":"C3G and ig-MPGN-treatment standard","volume":"39","author":"Noris","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: A single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179477","article-title":"Navigating the complement pathway to optimize PNH treatment with pegcetacoplan and other currently approved complement inhibitors","volume":"25","author":"Hillmen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024qdwvz5bg","article-title":"VALIANT: A randomized, multicenter, double-blind, placebo (PBO)-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN): SA-OR92","volume":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.10.023","article-title":"Iptacopan reduces proteinuria and stabilizes kidney function in C3 glomerulopathy","volume":"10","author":"Nester","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0348-z","article-title":"Utility of immunohistochemistry with C3d in C3 glomerulopathy","volume":"33","author":"Snijders","year":"2020","journal-title":"Mod Pathol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.399","article-title":"Membranoproliferative glomerulonephritis and\u00a0C3 glomerulopathy: resolving the confusion","volume":"81","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0049-0","article-title":"Membranoproliferative glomerulonephritis associated with autoimmune diseases","volume":"27","author":"Zand","year":"2014","journal-title":"J Nephrol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12882-018-0828-2","article-title":"Quantification of cancer risk in glomerulonephritis","volume":"19","author":"Heaf","year":"2018","journal-title":"BMC Nephrol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab078.0021","article-title":"Mo085monoclonal gammopathy of unknown significance among membranoproliferative glomerulonephritis patients","volume":"36","author":"Kovala","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.195","article-title":"Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits","volume":"88","author":"Larsen","year":"2015","journal-title":"Kidney Int"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.09.007","article-title":"Membranoproliferative glomerulonephritis: the role for laser microdissection and mass spectrometry","volume":"63","author":"Jain","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.06.015","article-title":"Monoclonal gammopathy of renal significance causes C3 glomerulonephritis via monoclonal igG kappa inhibition of complement factor H","volume":"6","author":"Johnson","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098432","article-title":"Clinico-pathogenic similarities and differences between infection-related glomerulonephritis and C3 glomerulopathy","volume":"24","author":"Wada","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/IJNRD.S285302","article-title":"C4d at crossroads between post-infectious glomerulonephritis and C3 glomerulopathy","volume":"14","author":"Bashir","year":"2021","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-factor B antibodies and acute postinfectious GN in children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019050515","article-title":"CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"31","author":"Zipfel","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.26355\/eurrev_202310_34179","article-title":"Clinical research advances\u00a0of\u00a0CFHR5 nephropathy: a recent review","volume":"27","author":"Fei","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720183","article-title":"FHR-5 serum levels and CFHR5 genetic variations in patients with immune complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy","volume":"12","author":"Garam","year":"2021","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13156","article-title":"Alternative pathway diagnostics","volume":"313","author":"Thurman","year":"2023","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1747678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:28:06Z","timestamp":1771928886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1747678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":105,"alternative-id":["10.3389\/fneph.2026.1747678"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1747678","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1747678"}}